ALZHEIMER’S TRIALS HAVE BEEN A GRAVEYARD OF FAILURES, because the patient pool is either too heterogeneous, or too far gone to rescue, or both, in later stage disease. It appeared self-evident that moving earlier into Mild Cognitive Impairment (MCI) could at least deal with the far-gone issue. At last FDA has acknowledged the seriousness of the trial problem, and devised more realistic goals for trials. Shame it has taken so long.
http://lnkd.in/WEnYkf
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022